What is the projected market valuation of the Oral Transmucosal Drug Market by 2035?

The Oral Transmucosal Drug Market is projected to reach approximately 11.99 USD Billion by 2035. Read More

What was the market valuation of the Oral Transmucosal Drug Market in 2024?

In 2024, the market valuation of the Oral Transmucosal Drug Market was 5.732 USD Billion. Read More

What is the expected CAGR for the Oral Transmucosal Drug Market during the forecast period 2025 - 2035?

The expected CAGR for the Oral Transmucosal Drug Market during the forecast period 2025 - 2035 is 6.94%. Read More

Which therapeutic area is projected to have the highest market value in the Oral Transmucosal Drug Market?

Pain Management is projected to have the highest market value, with an increase from 2.8664 USD Billion to 5.99 USD Billion. Read More

What are the leading companies in the Oral Transmucosal Drug Market?

Key players in the Oral Transmucosal Drug Market include Purdue Pharma, Mylan, Teva Pharmaceuticals, and Johnson & Johnson. Read More

How does the market for buccal administration compare to sublingual administration in terms of projected growth?

The buccal route is expected to grow from 2.293 USD Billion to 4.74 USD Billion, while sublingual administration is projected to increase from 3.439 USD Billion to 7.25 USD Billion. Read More

What drug type segment is anticipated to see the most growth in the Oral Transmucosal Drug Market?

Buprenorphine is anticipated to see substantial growth, increasing from 1.5 USD Billion to 3.2 USD Billion. Read More

Which formulation type is expected to dominate the Oral Transmucosal Drug Market by 2035?

Tablets are expected to dominate the market, with a projected increase from 1.8 USD Billion to 3.8 USD Billion. Read More

What is the projected market value for the Fentanyl segment by 2035?

The Fentanyl segment is projected to grow from 1.2 USD Billion to 2.5 USD Billion by 2035. Read More

How does the Oral Transmucosal Drug Market's growth compare to other pharmaceutical markets?

The Oral Transmucosal Drug Market's growth appears robust, with a projected valuation increase of over 6.94% CAGR from 2025 - 2035. Read More

What is the projected market size of the Global Oral Transmucosal Drug Market in 2024?

The Global Oral Transmucosal Drug Market is projected to be valued at 6.57 USD Billion in 2024. Read More

What will be the market size of the Global Oral Transmucosal Drug Market by 2035?

By 2035, the Global Oral Transmucosal Drug Market is expected to reach a value of 12.0 USD Billion. Read More

What is the expected CAGR for the Global Oral Transmucosal Drug Market from 2025 to 2035?

The expected CAGR for the Global Oral Transmucosal Drug Market from 2025 to 2035 is 5.62%. Read More

Which region holds the largest market share in the Global Oral Transmucosal Drug Market in 2024?

North America holds the largest market share in the Global Oral Transmucosal Drug Market, valued at 3.22 USD Billion in 2024. Read More

What is the market size of the Analgesics segment in the Global Oral Transmucosal Drug Market for 2024?

The Analgesics segment in the Global Oral Transmucosal Drug Market is valued at 2.31 USD Billion in 2024. Read More

What is the projected market value for Antipsychotics in the Global Oral Transmucosal Drug Market by 2035?

The Antipsychotics segment is projected to reach a market value of 3.05 USD Billion by 2035. Read More

Who are the key players in the Global Oral Transmucosal Drug Market?

Key players in the Global Oral Transmucosal Drug Market include Roche, Mylan, Catalent, Johnson and Johnson, and Pfizer. Read More

What is the expected market growth rate for the APAC region in the Global Oral Transmucosal Drug Market from 2024 to 2035?

The APAC region is expected to grow from 1.05 USD Billion in 2024 to 2.1 USD Billion by 2035. Read More

What is the projected market value for the Hormones segment by 2035?

The Hormones segment is expected to reach a market value of 2.75 USD Billion by 2035. Read More

What challenges and opportunities exist in the Global Oral Transmucosal Drug Market?

The market is witnessing challenges due to regulatory complexities, while opportunities arise from the increasing demand for faster drug delivery systems. Read More

Oral Transmucosal Drug Market

Oral Transmucosal Drug Market Research Report By Drug Type (Buprenorphine, Fentanyl, Midazolam, Nitroglycerin, Other Analgesics), By Formulation Type (Lozenges, Films, Tablets, Sprays), By Therapeutic Area (Pain Management, Anesthesia, Cardiovascular, Neurological Disorders), By Route of Administration (Sublingual, Buccal) andBy Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

6.94%

2024 Market Size

$ 5.73 Billion

2035 Market Size

$ 11.99 Billion

Pharmaceutical ● Updated August 2026 Report ID: MRFR/Pharma/40636-HCR | Pages: 200 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Drug Type (USD Billion) | |
  1. 4.1.1 Buprenorphine | |
  2. 4.1.2 Fentanyl | |
  3. 4.1.3 Midazolam | |
  4. 4.1.4 Nitroglycerin | |
  5. 4.1.5 Other Analgesics |
2. 4.2 Healthcare, BY Formulation Type (USD Billion) | |
  1. 4.2.1 Lozenges | |
  2. 4.2.2 Films | |
  3. 4.2.3 Tablets | |
  4. 4.2.4 Sprays |
3. 4.3 Healthcare, BY Therapeutic Area (USD Billion) | |
  1. 4.3.1 Pain Management | |
  2. 4.3.2 Anesthesia | |
  3. 4.3.3 Cardiovascular | |
  4. 4.3.4 Neurological Disorders |
4. 4.4 Healthcare, BY Route of Administration (USD Billion) | |
  1. 4.4.1 Sublingual | |
  2. 4.4.2 Buccal |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Purdue Pharma (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Mylan (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Teva Pharmaceuticals (IL) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 AstraZeneca (GB) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Johnson & Johnson (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Boehringer Ingelheim (DE) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Novartis (CH) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 AbbVie (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 GSK (GB) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY DRUG TYPE |
7. 6.4 US MARKET ANALYSIS BY FORMULATION TYPE |
8. 6.5 US MARKET ANALYSIS BY THERAPEUTIC AREA |
9. 6.6 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
10. 6.7 CANADA MARKET ANALYSIS BY DRUG TYPE |
11. 6.8 CANADA MARKET ANALYSIS BY FORMULATION TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY THERAPEUTIC AREA |
13. 6.10 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY DRUG TYPE |
16. 6.13 GERMANY MARKET ANALYSIS BY FORMULATION TYPE |
17. 6.14 GERMANY MARKET ANALYSIS BY THERAPEUTIC AREA |
18. 6.15 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
19. 6.16 UK MARKET ANALYSIS BY DRUG TYPE |
20. 6.17 UK MARKET ANALYSIS BY FORMULATION TYPE |
21. 6.18 UK MARKET ANALYSIS BY THERAPEUTIC AREA |
22. 6.19 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
23. 6.20 FRANCE MARKET ANALYSIS BY DRUG TYPE |
24. 6.21 FRANCE MARKET ANALYSIS BY FORMULATION TYPE |
25. 6.22 FRANCE MARKET ANALYSIS BY THERAPEUTIC AREA |
26. 6.23 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
27. 6.24 RUSSIA MARKET ANALYSIS BY DRUG TYPE |
28. 6.25 RUSSIA MARKET ANALYSIS BY FORMULATION TYPE |
29. 6.26 RUSSIA MARKET ANALYSIS BY THERAPEUTIC AREA |
30. 6.27 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
31. 6.28 ITALY MARKET ANALYSIS BY DRUG TYPE |
32. 6.29 ITALY MARKET ANALYSIS BY FORMULATION TYPE |
33. 6.30 ITALY MARKET ANALYSIS BY THERAPEUTIC AREA |
34. 6.31 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
35. 6.32 SPAIN MARKET ANALYSIS BY DRUG TYPE |
36. 6.33 SPAIN MARKET ANALYSIS BY FORMULATION TYPE |
37. 6.34 SPAIN MARKET ANALYSIS BY THERAPEUTIC AREA |
38. 6.35 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY DRUG TYPE |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY FORMULATION TYPE |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC AREA |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY DRUG TYPE |
45. 6.42 CHINA MARKET ANALYSIS BY FORMULATION TYPE |
46. 6.43 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA |
47. 6.44 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
48. 6.45 INDIA MARKET ANALYSIS BY DRUG TYPE |
49. 6.46 INDIA MARKET ANALYSIS BY FORMULATION TYPE |
50. 6.47 INDIA MARKET ANALYSIS BY THERAPEUTIC AREA |
51. 6.48 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
52. 6.49 JAPAN MARKET ANALYSIS BY DRUG TYPE |
53. 6.50 JAPAN MARKET ANALYSIS BY FORMULATION TYPE |
54. 6.51 JAPAN MARKET ANALYSIS BY THERAPEUTIC AREA |
55. 6.52 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY DRUG TYPE |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY FORMULATION TYPE |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC AREA |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
60. 6.57 MALAYSIA MARKET ANALYSIS BY DRUG TYPE |
61. 6.58 MALAYSIA MARKET ANALYSIS BY FORMULATION TYPE |
62. 6.59 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC AREA |
63. 6.60 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
64. 6.61 THAILAND MARKET ANALYSIS BY DRUG TYPE |
65. 6.62 THAILAND MARKET ANALYSIS BY FORMULATION TYPE |
66. 6.63 THAILAND MARKET ANALYSIS BY THERAPEUTIC AREA |
67. 6.64 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
68. 6.65 INDONESIA MARKET ANALYSIS BY DRUG TYPE |
69. 6.66 INDONESIA MARKET ANALYSIS BY FORMULATION TYPE |
70. 6.67 INDONESIA MARKET ANALYSIS BY THERAPEUTIC AREA |
71. 6.68 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
72. 6.69 REST OF APAC MARKET ANALYSIS BY DRUG TYPE |
73. 6.70 REST OF APAC MARKET ANALYSIS BY FORMULATION TYPE |
74. 6.71 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC AREA |
75. 6.72 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY DRUG TYPE |
78. 6.75 BRAZIL MARKET ANALYSIS BY FORMULATION TYPE |
79. 6.76 BRAZIL MARKET ANALYSIS BY THERAPEUTIC AREA |
80. 6.77 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
81. 6.78 MEXICO MARKET ANALYSIS BY DRUG TYPE |
82. 6.79 MEXICO MARKET ANALYSIS BY FORMULATION TYPE |
83. 6.80 MEXICO MARKET ANALYSIS BY THERAPEUTIC AREA |
84. 6.81 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
85. 6.82 ARGENTINA MARKET ANALYSIS BY DRUG TYPE |
86. 6.83 ARGENTINA MARKET ANALYSIS BY FORMULATION TYPE |
87. 6.84 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC AREA |
88. 6.85 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG TYPE |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY FORMULATION TYPE |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC AREA |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DRUG TYPE |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY FORMULATION TYPE |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC AREA |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DRUG TYPE |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY FORMULATION TYPE |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC AREA |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
102. 6.99 REST OF MEA MARKET ANALYSIS BY DRUG TYPE |
103. 6.100 REST OF MEA MARKET ANALYSIS BY FORMULATION TYPE |
104. 6.101 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC AREA |
105. 6.102 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY DRUG TYPE, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY DRUG TYPE, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Oral Transmucosal Drug Market Segmentation

Oral Transmucosal Drug Market By Drug Type (USD Billion, 2025-2035)

Buprenorphine
Fentanyl
Midazolam
Nitroglycerin
Other Analgesics

Oral Transmucosal Drug Market By Formulation Type (USD Billion, 2025-2035)

Lozenges
Films
Tablets
Sprays

Oral Transmucosal Drug Market By Therapeutic Area (USD Billion, 2025-2035)

Pain Management
Anesthesia
Cardiovascular
Neurological Disorders

Oral Transmucosal Drug Market By Route of Administration (USD Billion, 2025-2035)

Sublingual
Buccal

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”